On March 13, 2026, the U.S. Food and Drug Administration (FDA) expanded the approval of GSK's RSV vaccine, Arexvy, to include adults aged 18 to 49 years who are at increased risk for severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). This approval follows the initial authorization for older adults and aims to broaden the vaccination strategy in younger high-risk populations. The vaccine is administered as a single dose and is designed to help prevent serious RSV infections that can lead to hospitalization and other complications.

This expansion of Arexvy's indication is significant for healthcare providers as RSV has been recognized as a common cause of severe respiratory illness, particularly in vulnerable populations. The CDC estimates that RSV leads to substantial morbidity among adults, especially those with underlying health conditions. By including younger adults in the vaccination recommendations, the FDA aims to reduce the incidence of RSV-related hospitalizations and improve public health outcomes. This change is timely, as RSV typically circulates in the fall and winter months, and vaccination efforts can be optimized to coincide with this seasonal pattern.

What Happened

Why It Matters

What Changed

  • Arexvy is now approved for adults aged 18 to 49 years who are at increased risk for severe RSV disease, in addition to its previous approval for those aged 60 and older [1].
  • The vaccine is administered as a single intramuscular dose of 0.5 mL [2].
  • The CDC recommends vaccination for adults aged 75 years and older, as well as those aged 50 to 74 years with specific risk factors, which now includes younger adults with similar risk profiles [3].
  • Risk factors for severe RSV illness include chronic lung disease, cardiovascular disease, diabetes, and other immunocompromising conditions [1].
  • A postmarketing observational study indicated a potential increased risk of Guillain-Barré syndrome within 42 days following vaccination, which healthcare providers should monitor [2].

What This Means for Your Practice

Healthcare providers, particularly those in primary care and infectious disease specialties, should begin integrating the expanded use of Arexvy into their vaccination protocols for high-risk adults aged 18 to 49. Clinicians should assess patients for risk factors associated with severe RSV disease, such as chronic respiratory conditions or significant obesity, and recommend vaccination accordingly. It is crucial to educate patients about the benefits of vaccination in preventing severe RSV outcomes, especially as RSV season approaches. Additionally, monitoring for adverse events, particularly Guillain-Barré syndrome, will be essential in the post-vaccination period. How will you approach patient education regarding this new indication and its associated risks?

Sources and Further Reading

  • Centers for Disease Control and Prevention — RSV Vaccine Guidance for Adults | RSV | CDC. URL: https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html
  • Centers for Disease Control and Prevention — Respiratory Syncytial Virus (RSV) Vaccine Safety | Vaccine Safety | CDC. URL: https://www.cdc.gov/vaccine-safety/vaccines/rsv.html
  • Centers for Disease Control and Prevention — Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 | MMWR. URL: https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm